64 completed, 16 unknown, 15 recruiting, 13 terminated. 123 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 123 | Completed 64, Unknown 16, Recruiting 15, Terminated 13, Active not recruiting 6, Not yet recruiting 4, Suspended 2, Withdrawn 2, Enrolling by invitation 1 |
Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy) - Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis) | Phase 4 | Not yet recruiting | University Hospital, Toulouse | 30 | 2027-02-01 | 2026-11-05 |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Recruiting | University of Miami | 35 | 2026-11-30 | 2026-11-02 |
| Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer. Darolutamide, Physician choice Androgen Deprivation (Hormone) Therapy - Prostate Cancer | Phase 4 | Not yet recruiting | University of Chicago | 80 | 2026-11-01 | 2026-01-08 |
| Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients. Experimental - Elderly, Breast Cancer | Phase 4 | Not yet recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 794 | 2026-09-01 | 2026-09-03 |
| Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence fluciclovine (18F) - Prostate Cancer | Phase 4 | Recruiting | Blue Earth Diagnostics | 142 | 2026-08-31 | 2026-11-05 |
| Autonomic and Renal Contributions to Hypertension With ADT Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo - Androgen Deprivation Therapy, Prostate Cancer | Phase 4 | Recruiting | Virginia Commonwealth University | 60 | 2026-08-01 | 2026-11-02 |
| 177Lu-PSMA-617 Combined With Darolutamide in Neoadjuvant Treatment of High-risk Localized Prostate Cancer: a Prospective, Single-arm, Multi-center Clinical Trial Darolutamide combined with 177Lu-PSMA-617 - Prostate Cancer, Prostate Cancer Patients | Phase 4 | Not yet recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 20 | 2026-07-01 | 2026-07-01 |
| Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers Morning administration of CDK4/6 inhibitor, Evening administration of CDK4/6 inhibitor, Morning administration of ARPI - Metastatic Breast Cancer, Metastatic Prostate Cancer | Phase 4 | Recruiting | Ottawa Hospital Research Institute | 50 | 2026-02-02 | 2026-07-17 |
| Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy Semaglutide Pen Injector - Prostate Cancer | Phase 4 | Active not recruiting | Hamilton Health Sciences Corporation | 20 | 2025-07-02 | 2026-09-14 |
| COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer Darolutamide Oral Tablet, leuprorelin - Prostate Cancer | Phase 4 | Active not recruiting | Brazilian Clinical Research Institute | 144 | 2025-02-17 | 2026-10-30 |
| Impact of Using the Airseal System With Ultra-low Pneumoperitoneum in Patients Undergoing Robot-assisted Radical Prostatectomy: A Prospective, Comparative, Randomized Clinical Study. The Conventional Insufflation System, AirSeal® System - Prostate Carcinoma, Prostate Neoplasm | Phase 4 | Recruiting | Brazilian Institute of Robotic Surgery | 200 | 2025-02-01 | 2025-01-20 |
| Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging - Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8 | Phase 4 | Recruiting | Roswell Park Cancer Institute | 600 | 2025-01-15 | 2026-05-14 |
| 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer 18F-Fluciclovine PET/CT Scan - Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 4 | Recruiting | VA Greater Los Angeles Healthcare System | 15 | 2024-12-15 | 2024-11-27 |
| Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy flotufolastat (18F), piflufolastat (18F) - Prostate Cancer | Phase 4 | Completed | Blue Earth Diagnostics | 62 | 2024-12-04 | 2026-07-13 |
| Prostate MRI and Pylarify PSMA PET/CT Pylarify Piflufolastat Flourine-18 (18F-DCFPyL) - Prostate Cancer | Phase 4 | Withdrawn | Corewell Health East | 2024-10-01 | 2025-01-03 | |
| PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer 18F-rhPSMA-7.3, PET/CT - Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer | Phase 4 | Active not recruiting | Brigham and Women's Hospital | 20 | 2024-06-30 | 2026-10-29 |
| Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study) Oxycodone oral capsule 15 mg, Abiraterone Acetate Tablets 500 mg - Prostate Cancer, Pain Cancer | Phase 4 | Recruiting | Deventer Ziekenhuis | 29 | 2024-04-12 | 2025-06-03 |
| Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan 18F-DCFPyl - Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 4 | Recruiting | Brigham and Women's Hospital | 30 | 2024-04-01 | 2026-01-29 |
| Prothrombin Complex Concentrate vs Fresh Frozen Plasma in Goal-directed Bleeding Management in Non-cardiac Surgery fresh frozen plasma, prothrombin complex concentrate - Prostate Cancer, Spine, Open | Phase 4 | Unknown | Konkuk University Medical Center | 154 | 2024-03-01 | 2024-01-02 |
| Laparoscopic TAP Block During Robotic Assisted Laparoscopic Radical Prostatectomy for Improvement in Postoperative Pain Early TAP Block, Late TAP Block - Prostate Cancer | Phase 4 | Enrolling by invitation | Corewell Health East | 94 | 2024-02-19 | 2026-04-23 |
Showing 20 of 123. Sign in to see all of them.
Breast Neoplasms (9) · Neoplasms (8) · Neoplasm Metastasis (5) · Kidney Neoplasms (4) · Pain (4) · Colonic Neoplasms (3) · Kidney Diseases (3) · Prostatic Hyperplasia (3) · Prostatic Neoplasms, Castration-Resistant (3) · Anxiety Disorders (2) · Erectile Dysfunction (2) · Hot Flashes (2) · Hypertension (2) · Liver Neoplasms (2)
Genital Diseases (123) · Genital Diseases, Male (122) · Genital Neoplasms, Male (122) · Male Urogenital Diseases (122) · Neoplasms by Site (122) · Urogenital Diseases (122) · Urogenital Neoplasms (122) · Prostatic Diseases (121) · Neoplasms (115) · Pathological Conditions, Signs and Symptoms (19) · Pathologic Processes (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Digestive System Diseases (10) · Signs and Symptoms (10)
Zoledronic Acid (14) · Leuprolide (10) · bicalutamide (7) · Goserelin (6) · Triptorelin Pamoate (6) · enzalutamide (6) · Dutasteride (5) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (5) · luprolide acetate gel depot (5) · Flutamide (4) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (3) · Abiraterone Acetate (3) · Androgen Antagonists (3) · Magnetic Resonance Spectroscopy (3) · Prednisone (3)
Novartis Pharmaceuticals (10) · Novartis (4) · GlaxoSmithKline (3) · Radboud University Medical Center (3) · Sanofi (3) · Astellas Pharma Inc (2) · AstraZeneca (2) · Blue Earth Diagnostics (2) · Brigham and Women's Hospital (2) · Columbia University (2) · Corewell Health East (2) · Ipsen (2) · Johns Hopkins University (2) · Konkuk University Medical Center (2) · M.D. Anderson Cancer Center (2)
United States (49) · Canada (13) · Netherlands (9) · France (8) · South Korea (7) · Brazil (6) · Germany (6) · Italy (6) · Spain (6) · China (5) · Denmark (5) · United Kingdom (5) · Belgium (4) · Finland (4) · Russia (4)
Heather Jacene, MD (2) · Matthew Babcock, PhD (2) · Ahmed Aly (1) · Ahmed Elshal, MD (1) · Albert DeNittis, MD (1) · Ana-Alicia Beltran-Bless, MD (1) · Anne Sophie P. Kancir, MD PhD (1) · Badar Mian, MD (1)
PMID 10524880, PMID 14713808, PMID 15249979, PMID 15310998, PMID 15592069, PMID 17724727, PMID 18708295, PMID 19143027, PMID 22405509, PMID 23186377, PMID 24354113, PMID 25627076, PMID 25988518, PMID 27286961, PMID 30028657, PMID 30224019, PMID 30300367, PMID 30352714, PMID 30939628, PMID 31329922, PMID 31643128, PMID 31797684, PMID 32444264, PMID 32632561, PMID 33258023, PMID 33299276, PMID 34068083, PMID 34350976, PMID 35280654, PMID 35422136, PMID 35671523, PMID 35971857, PMID 36419331, PMID 36480560, PMID 37101774, PMID 38485614, PMID 38656229, PMID 40389061, PMID 41729277, PMID 41888042, PMID 4723349, PMID 7714876
2023 (2), 2025 (1), K01HL164978 (1), R01CA138627 (1)